AGL arrives at its August 5 earnings report having lost 6.5% over the past week and 14.5% over the past month — but options traders are still leaning heavily into the upside story, even as the analyst community remains sharply divided.
The clearest read on near-term sentiment is in the options market. The put/call ratio fell further to 0.15 on July 31, now running more than three standard deviations below its 20-day average of 0.23. That is an extreme call-side skew. Traders are not hedging into this print — they are positioned for another sharp move higher. The context matters here: the last earnings release in May triggered a 127% single-day gain, followed by a 169% five-day move. The June print was the hangover, with shares falling 10.6% the next day. With results four days away, options positioning reflects a market that has not forgotten what happened in May.
Short interest tells a much quieter story. Shorts account for just 0.21% of the free float — a negligible level. That said, the directional shift is worth noting: short interest has risen 19% week-on-week and 39% over the past month, stepping up from roughly 640,000 shares to 863,000 shares. Borrow cost remains cheap at 0.90%, up sharply from 0.38% three weeks ago but still low in absolute terms. Availability is extremely loose at 4,318% — meaning shares to borrow vastly outnumber shares already borrowed. There is no squeeze pressure here. The rise in shorts looks more like cautious hedging ahead of earnings than a structural bear thesis building.
Analyst opinion is the most contested part of the AGL picture right now. Citigroup downgraded to Sell on July 23, even while lifting its target from $80 to $105 — flagging ongoing concern about utilization visibility. Wells Fargo took the opposite view earlier in the month, raising its target to $141 while keeping an Overweight rating. The consensus mean target is $78, well below the current price of $91.61. That gap is the central tension: the stock has rallied more than 475% year-to-date on the back of 44% revenue growth and 36% Medicare Advantage membership expansion, yet the average analyst still sees material downside from here. The bull case rests on membership momentum and improving medical cost trends. The bear case points to persistent visibility problems in the second half and an adjusted EBITDA loss that came in far below expectations in Q4 2024. Factor scores add a nuance: the EPS surprise rank is outstanding at the 95th percentile, and the sector score hits 88th percentile — but EPS momentum over 90 days ranks just 3rd percentile, and the analyst recommendation differential scores only 5th percentile, reflecting just how divided the Street remains.
Institutional ownership is concentrated. Clayton, Dubilier & Rice holds nearly 24% of shares outstanding and made no change through June 30. Morgan Stanley Investment Management holds 12.4% of shares, also unchanged through the last reporting date. AQR added 559,750 shares in the most recent quarter — a meaningful build. Insider activity is one-directional: all recent trades have been sales, including a $258,000 CFO sale in July. The amounts are individually modest, but the pattern is consistent. No insider buying has appeared in recent months.
Peer performance adds modest context. HUM fell 6.5% on the week — nearly identical to AGL's decline. LFST dropped 3.9%. CLOV lost 3.5%. The weakness in AGL is not idiosyncratic — the managed care and value-based care space broadly sold off this week. That makes the absolute move in AGL less alarming, but it also means any positive earnings surprise will need to overcome sector-level headwinds rather than simply ride a rising tide.
The August 5 print is therefore less about whether membership is still growing and more about whether management can demonstrate improved visibility into second-half utilization — the precise issue that has tripped the stock before and that prompted Citi's Sell rating just days ago.
See the live data behind this article on ORTEX.
Open AGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
